Prihlásiť sa Zaregistrujte sa zadarmo

Akcie v obehu spoločnosti Cue Biopharma Inc

Aká je hodnota metriky Akcie v obehu spoločnosti Cue Biopharma Inc?

Hodnota metriky Akcie v obehu spoločnosti Cue Biopharma Inc je 0.000 0.00%

Aká je definícia metriky Akcie v obehu?

Akcie v obehu (Shares float) je podiel akcií spoločnosti vlastnených verejnými investormi voči zablokovaným akciám (nie sú voľne v obehu).

Shares float represents the portion of shares of a corporation that are in the hands of public investors as opposed to locked-in stock held by promoters, company officers, controlling-interest investors, or government. This number is sometimes seen as a better way of calculating market capitalization because it provides a more accurate reflection of what public investors consider the company to be worth. In this context, the float may refer to all the shares outstanding that can be publicly traded

The float is calculated by subtracting the locked-in shares from outstanding shares. Stocks with smaller floats tend to be more volatile than those with larger floats. In general, the large holdings of founding shareholders, corporate cross-holdings, and government holdings in partially privatized companies are excluded when calculating the size of a public float.

Akcie v obehu spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Cue Biopharma Inc

Čomu sa venuje spoločnosť Cue Biopharma Inc?

cue biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. we design biologics to engage and modulate the activity of disease-associated t cells in the patient’s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. we believe our biologics allow us to target antigen-specific t cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the cue biologics platform. this flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. headquartered in kendall square, cambridge, ma, we are led by an experienced management team and sci

Firmy s metrikou akcie v obehu podobnou spoločnosti Cue Biopharma Inc